Drugs / DS-6051b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02675491 | Feb 2016 → Dec 2021 | cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02279433 | Sep 2014 → Mar 2019 | cancer | Nuvation Bio Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-6051b | “DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK).” NCT02279433 ↗ |
| Action | Inhibit | “inhibitor of the tyrosine kinases (ROS1)” NCT02279433 ↗ |
| Route | Oral | “oral administration” NCT02279433 ↗ |
| Target | ROS1 | “inhibitor of the tyrosine kinases (ROS1)” NCT02279433 ↗ |